提奥斯特通过降低c-FLIP/SMAD2/3信号通路的调节来抑制三阴性乳腺癌
Wen-Die Wang1, Chao-Yang Zeng1, Yue Shang1
1Department of Cancer Research, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing 100050, China.
Journal of Asian natural products research
|April 18, 2024
概括
提奥斯特普顿通过向c-FLIP/SMAD2/3通路来对抗三阴性乳腺癌 (TNBC). 这项研究揭示了thio-strepton的新型分子机制.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 三阴性乳腺癌 (TNBC) 是一种具有有限治疗选择和不良预后的侵袭性亚型.
- 斯特是一种天然化合物,在各种癌症中表现出抗瘤作用,包括TNBC.
研究的目的:
- 阐明底层的新型分子机制的thiostrepton的抗瘤活动在TNBC.
- 为了研究c-FLIP/SMAD2/3信号通路在列的疗效中的作用.
主要方法:
- 使用了MDA-MB-231 TNBC细胞系.
- 评估了细胞活力,c-FLIP表达和SMAD2/3酸化.
- 使用过度基因表达 (c-FLIP) 和淘汰 (SMAD2/3) 技术.
主要成果:
- 提奥斯特普顿抑制了MDA-MB-231细胞活力,降低了c-FLIP和p-SMAD2/3水平.
- 过度表达c-FLIP降低了列敏感性,而SMAD2/3敲击增强了它.
- 调节c-FLIP影响了SMAD2/3的表达和酸化,反之亦然.
结论:
- 这项研究确定了c-FLIP/SMAD2/3信号通路是thio-strepton在TNBC中抗瘤作用的新机制.
- 研究结果表明,潜在的治疗策略是针对这一途径进行TNBC治疗.
相关概念视频
TGF - β Signaling Pathway
7.3K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.3K
Receptor Downregulation in MVBs
2.1K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.1K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
PI3K/mTOR/AKT Signaling Pathway
3.5K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.5K


